This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Targacept Trial Tragedy Takeaway: Don't Trust Clinical Data From India

WINSTON-SALEM, NC ( TheStreet) -- The lesson from Tuesday's Targacept (TRGT) TC-5214 tragedy: Never trust clinical data from India.

I repeat: Never trust clinical data from India.

Clinical trials conducted in Russia aren't any more credible, so don't trust data from there either.

I should have had this lesson permanently seared into my brain after making a bad call on Medivation (MDVN - Get Report) and its Alzheimer's drug (clinical data from Russia.) But stupid me, I blew it again by predicting success for Targacept and its anti-depressant TC-5214 (clinical data from India.)

Any hope that something positive could be salvaged from the failed TC-5214 phase III study were pretty much dashed this morning when Targacept's CEO, speaking on a conference call, said '5214's effect didn't separate at all from placebo.

If '5214 didn't perform any better than a placebo in alleviating symptoms of depression in this phase III study, the chance that the drug performs any better in the remaining three phase III studies is really low.

And that also means the spectacular data generated from the phase IIb study of TC-5214, conducted largely in India, were a mirage.

It's difficult to reach any other conclusion although Targacept on Tuesday's call insisted that the phase IIb study was conducted with diligence and that its partner AztraZeneca (AZN - Get Report) did a lot of confirmatory work before agreeing to license TC-5214 for blockbuster terms.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIOD $0.42 0.12%
AZN $29.27 -0.51%
MDVN $56.17 7.92%
LLY $76.46 -0.07%
TRGT $1.55 0.01%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs